Nominations deadline extended to July 29
Enter now

Oxford life sciences cluster to gain new office and lab facility

By Stephen Emerson
2 February 2022

A new purpose-built centre is to be added to the thriving Oxford life sciences cluster.

Breakthrough Properties, a joint venture between Tishman Speyer and Bellco Capital, has announced that it will be acquiring the 1.7-acre Trinity House site located at the gateway of the 88-acre Oxford Business Park with a view to creating a purpose-built, Class A office and lab environment.

The site, which sits close to Oxford University, is part of a cluster recognised as one of the leading global markets in biomedical and life sciences development.

READ MORE: South East life sciences: round-up of main stories in January

Dan Belldegrun, CEO of Breakthrough Properties, said: "Oxford has long enjoyed the highest caliber academic research and talent driving innovation and discovery.

"What has been lacking is the life science infrastructure and ecosystems to properly support that growth.

"We are thrilled by this opportunity to deliver a best-in-class, purpose-built research and development center to support innovators within Oxford's thriving life sciences cluster."

The Oxford life science cluster is currently home to such leading UK firms as Oxford Biomedica, Immunocore and Adaptimmune.

Trinity House in Oxford

Tishman Speyer senior managing director, Bernard Penaud, said: "The local life sciences industry has experienced incredible and rapidly-accelerating growth, as evidenced by the record £4.5 billion raised by the UK biotech companies in 2021 alone. It is vital that the development community keep pace with this growth by producing the types of innovative, high-quality and customer-centric life science environments that Breakthrough will create at Oxford Business Park."

The Trinity House acquisition further adds to Breakthrough's growing pipeline of ground-up development projects, which also includes "The 105 by Breakthrough," a 263,500 square-foot life sciences facility in Boston that is fully leased to CRISPR Therapeutics, and "Torrey View by Breakthrough," a 10-acre campus in San Diego that is substantially preleased to BD Biosciences.

Thomas Renn, Breakthrough Properties vice president, acquisitions and development in Europe, said, "Trinity House represents a great opportunity for us to move quickly to bring the Breakthrough platform to the Golden Triangle, where there is a significant need for high quality lab provision to meet the growth of the cluster. We are eager to connect with scientific innovators and life science companies who align with our vision for the Oxford ecosystem and would value access to best-in-class research space, the Scientific Advisory Board and the broader Tishman Speyer and Bellco Capital network."

READ MORE: Oxford Biomedica to work with Virica Biotech on new gene therapy